Skin immune biomarker predicts the development of AD in the pediatric population
With a prevalence of 15-20%, atopic dermatitis (AD) is the most common skin disease in the pediatric population. At EADV 2022, The Barrier dysfunction in Atopic newBorns (BABY) study is ready to present results suggesting an essential role of immune biomarkers in predicting the development of AD during the first two years of life.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
